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SUPPLEMENTARY NOTES
ABSTRACT
The chemopreventive agent, sulforaphane (SFN) induces, Nfr-2-stabilization and Nrf2-dependent transcription in breast cancer cells. These effects of SFN are dependent upon PKC and PI3K/AKT pathways as well as the likely involvement of direct interactions between SFN and Keapl. SFN sensitizes breast cancer cells to the cytotoxicities of doxorubicin and peclitaxel. Co-treatment with the PKC inhibitor, Ro-31-8221, but not the PI3K inhibitor, LY294002, augments this sensitization by SFN. However, the utility of combined chemopreventive agent (SFN). And cancer drug (doxorubicin and paclitaxel treatment in breast cancer is potentially limited because SFN also sensitizes some non-cancerous cells to cancer drug toxicity. 
